Medicine
Erythromycin 250 mg tablet
Erythromycin 250 mg tablet is a generic prescription medicine for oral use, made by 13 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store below 86°F (30°C).
Key facts
- Active ingredient (INN)
- Erythromycin
- Brand
- Sold under the generic name
- Strength
- 250 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 30 tablets, 100 tablets, 1000 tablets and 34 more
- Manufacturers
- Alembic PharmaceuticalsIndiaZydus LifesciencesIndiaAscend LaboratoriesIndiaTorrent PharmaceuticalsIndiaCadila PharmaceuticalsIndiaPD-Rx PharmaceuticalsA-S Medication SolutionsArbor PharmaceuticalsModavar PharmaceuticalsOrange Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store below 86°F (30°C).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- D10AF02 Erythromycin
- HS code (indicative)
- 3004.20Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 6 September 2011
- Identifiers
- RxCUI 197650, 598006DailyMed set ID f2efbc94-64f7-4130-ab23-e5983854f730, e54d66fa-93bb-4339-a75e-194a2e4488aa, 904b9ab6-9a2a-47f3-8a38-04920ce696e0 +12NDC 52536-103, 55289-075, 46708-397 +12Application ANDA061621, ANDA215661, ANDA213628 +4
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 tablet, film coated in 1 bottle | 46708-397-30 | Alembic PharmaceuticalsIndia | 28 August 2023 |
| 100 tablet, film coated in 1 bottle | 46708-397-31 | Alembic PharmaceuticalsIndia | 28 August 2023 |
| 1000 tablet, film coated in 1 bottle | 46708-397-91 | Alembic PharmaceuticalsIndia | 28 August 2023 |
| 30 tablet, film coated in 1 bottle | 62332-397-30 | Alembic PharmaceuticalsIndia | 28 August 2023 |
| 100 tablet, film coated in 1 bottle | 62332-397-31 | Alembic PharmaceuticalsIndia | 28 August 2023 |
| 1000 tablet, film coated in 1 bottle | 62332-397-91 | Alembic PharmaceuticalsIndia | 28 August 2023 |
| 100 tablet, film coated in 1 bottle | 70710-1047-1 | Zydus LifesciencesIndia | 30 June 2023 |
| 30 tablet, film coated in 1 bottle | 70710-1047-3 | Zydus LifesciencesIndia | 30 June 2023 |
| 500 tablet, film coated in 1 bottle | 70710-1047-5 | Zydus LifesciencesIndia | 30 June 2023 |
| 100 tablet, film coated in 1 bottle | 70771-1548-1 | Zydus LifesciencesIndia | 30 June 2023 |
| 30 tablet, film coated in 1 bottle | 70771-1548-3 | Zydus LifesciencesIndia | 30 June 2023 |
| 500 tablet, film coated in 1 bottle | 70771-1548-5 | Zydus LifesciencesIndia | 30 June 2023 |
| 100 tablet, film coated in 1 bottle | 67877-762-01 | Ascend LaboratoriesIndia | 14 July 2022 |
| 500 tablet, film coated in 1 bottle | 67877-762-05 | Ascend LaboratoriesIndia | 14 July 2022 |
| 30 tablet, film coated in 1 bottle | 67877-762-30 | Ascend LaboratoriesIndia | 14 July 2022 |
| 1 blister pack in 1 carton / 10 tablet, film coated in 1 blister pack | 67877-762-33 | Ascend LaboratoriesIndia | 14 July 2022 |
| 30 tablet, film coated in 1 bottle | 71209-100-01 | Cadila PharmaceuticalsIndia | 6 October 2021 |
| 100 tablet, film coated in 1 bottle | 71209-100-05 | Cadila PharmaceuticalsIndia | 6 October 2021 |
| 100 tablet, coated in 1 bottle | 13668-606-01 | Torrent PharmaceuticalsIndia | 6 July 2020 |
| 500 tablet, coated in 1 bottle | 13668-606-05 | Torrent PharmaceuticalsIndia | 7 July 2020 |
| 30 tablet, coated in 1 bottle | 13668-606-30 | Torrent PharmaceuticalsIndia | 12 April 2022 |
| 30 tablet, film coated in 1 bottle | 24338-102-03 | Arbor Pharmaceuticals | 20 November 2017 |
| 100 tablet, film coated in 1 bottle | 24338-102-13 | Arbor Pharmaceuticals | 6 September 2011 |
| 100 tablet, film coated in 1 bottle | 72241-036-05 | Modavar Pharmaceuticals | 31 July 2021 |
| 30 tablet, film coated in 1 bottle | 72241-036-22 | Modavar Pharmaceuticals | 31 July 2021 |
| 100 tablet, film coated in 1 bottle | 73082-010-01 | Orange Pharmaceuticals | 5 October 2019 |
| 30 tablet, film coated in 1 bottle | 73082-010-30 | Orange Pharmaceuticals | 5 October 2019 |
| 100 tablet, film coated in 1 bottle | 0093-5571-01 | Teva Pharmaceuticals | 4 May 2021 |
| 30 tablet, film coated in 1 bottle | 0093-5571-56 | Teva Pharmaceuticals | 4 May 2021 |
| 30 tablet, film coated in 1 bottle | 52536-103-03 | Wilshire Pharmaceuticals | 15 March 2018 |
| 100 tablet, film coated in 1 bottle | 52536-103-13 | Wilshire Pharmaceuticals | 15 March 2018 |
| 3 tablet, film coated in 1 bottle | 50090-5918-5 | A-S Medication Solutions | 14 February 2022 |
| 90 tablet, film coated in 1 bottle | 50090-5918-6 | A-S Medication Solutions | 9 June 2022 |
| 30 tablet, coated in 1 bottle | 51407-855-30 | Golden State Medical Supply | 7 December 2023 |
| 3 tablet, film coated in 1 bottle, plastic | 55289-075-03 | PD-Rx Pharmaceuticals | 18 December 2013 |
| 40 tablet, film coated in 1 bottle, plastic | 55289-075-40 | PD-Rx Pharmaceuticals | 18 December 2013 |
| 56 tablet, film coated in 1 bottle, plastic | 55289-075-56 | PD-Rx Pharmaceuticals | 18 December 2013 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 25 June 1964 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Erythromycin
Clinical summary
Erythromycin is a macrolide antimicrobial indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below, among other approved uses. MedsAcross supplies Erythromycin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about ErythromycinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Ery-Ped prescribing information (Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals)) · U.S. National Library of Medicine, DailyMed
Need Erythromycin 250 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.